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Objectives: A population- based controlled study to determine whether adult (55- 74 
years) neurological disease deaths are continuing to rise and are there significant dif-
ferences between America and the twenty developed countries 1989- 91 and 
2012- 14.
Method: Total Neurological Deaths (TND) rates contrasted against control Cancer and 
Circulatory Disease Deaths (CDD) extrapolated from WHO data. Confidence intervals 
compare USA and the other countries over the period. The Over- 75’s TND and popu-
lation increases are examined as a context for the 55- 74 outcomes.
Results: Male neurological deaths rose >10% in eleven countries, the other countries 
average rose 20% the USA 43% over the period. Female neurological deaths rose 
>10% in ten counties, averaging 14%, the USA up 68%. USA male and female neuro-
logical deaths increased significantly more than twelve and seventeen countries, re-
spectively. USA over- 75s population increased by 49%, other countries 56%. Other 
countries TND up 187% the USA rose fourfold. Male and female cancer and CDD fell 
in every country averaging 26% and 21%, respectively, and 64% and 67% for CDD. 
Male neurological rates rose significantly more than Cancer and CCD in every country; 
Female neurological deaths rose significantly more than cancer in 17 countries and 
every country for CDD. There was no significant correlation between increases in 
neurological deaths and decreases in control mortalities.
Conclusions: There are substantial increases in neurological deaths in most countries, 
significantly so in America. Rises in the 55- 74 and over- 75’s rates are not primarily due 
to demographic changes and are a matter of concern warranting further 
investigation.
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1  | INTRODUCTION
From neurological studies covering the later part of the 20th century, 
evidence is growing of increases in a range of neurological morbid-
ity and mortality especially related to Alzheimer’s and Amyotrophic 
Lateral Sclerosis (ALS), known as Motor Neurone Disease (MND) in 
Europe.1-4 The accumulation of evidence has continued to build in 
this century.5-8 The first international comparison of the changing 
neurological mortality was between 1979- 1981 and 1995- 1997 in 
twenty- one developed countries found that the dementias were start-
ing a decade earlier in a number of nations.5,7 This was followed- up 
in a second international study taking the results to 2010. The latter 
analysis used the later baseline years of 1989- 91, which confirmed the 
earlier onset of neurological morbidity and that neurological deaths 
continued to increase in the majority of the countries reviewed.1-12 
Rises in USA the over- 75s neurological deaths were considerable as 
the USA had significantly greater increases than fourteen of the other 
twenty nations, with threefold rises in American men and a fivefold 
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increase in women in just 21 years.8 Furthermore, there is a new in-
terest in neurological diseases in Latin America and Asia, with a rising 
incidence than previously, although the rates remain lower than those 
found in developed countries,2,12,13 suggesting this is increasingly a 
worldwide phenomenon.
The rises in neurological mortality have been questioned as an ar-
tefact, for example, due to improved diagnosis of ALS14 and the effect 
of changing demographics giving rise to the “Gompertzian hypoth-
esis.” This states that the neurological increases are a consequence 
of people living longer and therefore developing age- related dis-
eases that they had not lived long enough to develop previously.15-17 
However, the diagnostic issue has limited impact as it is mortality 
rates that are measured not separate diagnostic categories, and at 
this point, there is little evidence of diagnostic uncertainty as the 
primary cause of death is categorized as being due to a neurological 
condition.1,5-8 Moreover, the Gompertzian position appears to have 
ignored the marked changes between the sexes and in different coun-
tries.1,5-11 Crucially, the Gompertzian hypothesis does not account for 
the substantial rise in early onset dementia reported in many Western 
countries.12,13,18-22
To reduce a primarily Gompertzian explanation, this population- 
based study focuses upon people aged 55- 74 years, below life ex-
pectancies in the developed world and utilizes the latest WHO 
data, updated December 2016 to take the analysis up to 2014.23 
Consequently, studying the adults aged 55- 74 over a relatively short 
time means any Gompertzian influence will be minimal. However, to 
place the results on adults aged 55- 74 in a wider context, the over- 75s 
rates and matching population increases are also examined to explore 
any possible strengths of the Gompertzian influence.
Two control mortalities are juxtaposed against neurological death 
rates, Cancer Mortality and Circulatory Disease Deaths (CDD) because 
they are considered age related. It should be noted, however, that this 
analysis is not designed to postulate about possible aetiologies, but 
only to determine whether there continues to be substantial increases 
in neurological deaths over the past two decades and whether there 
are any significant differences in the US rates and the other nations.
There are four working null hypotheses; in each country between 
1989- 91 and 2012- 14 that there will be no statistically significant dif-
ferences between:
1. Total Neurological Deaths and Cancer Mortality;
2. Total Neurological Deaths and CDD,
3. between USA neurological death rates and the other twenty devel-
oped countries, and
4. no statistical association between rises in neurological deaths and 
falls in the control mortalities of Cancer and CDD.
2  | MATERIALS AND METHOD
This population- based study of the latest WHO mortality data, up-
dated December 2016, examines mortality rates per million (pm) 
of population of people aged 55- 74 years by sex. The categories 
are based upon the 10th edition of the International Classification 
of Diseases ensuring as uniform a categorization as possible.23 The 
WHO classifies neurological mortality under two broad categories, 
Nervous Disease Deaths (G00- G99), which include Parkinson’s disease, 
Motor Neurone Disease, Multiple Sclerosis, Multiple System Atrophy, 
etc. and Alzheimer’s disease and Other Dementias (F01- F03 G30- 31).23 
The two rates are combined to calculate a Total Neurological Death 
(TND) rate for the average baseline years for 1989- 91 with the av-
erage index years 2012- 14.23 Germany, Portugal and Spain baseline 
years are 1990- 92, and the few countries that have earlier index 
years, 2010- 12 and 2011- 13, are noted in the tables. Whilst the focus 
is upon people aged 55- 74, as a context for the 55- 74 results, the 
over- 75s TND rates and increases in population are also examined to 
indicate whether the rises in the elderly TND are primarily related to 
increased population.
The control mortality categories are Cancer Mortality (CM) (coded 
C00- D48, WHO, 2015) and the CDD (coded H100- 199).23 Each coun-
try is compared against its baseline and index years, and a ratio of 
change over the period is calculated.
An inherent problem of international comparisons is the reliability 
of the data as well as how differing health/social policies and health 
services influence health outcomes. Only country- specific research 
could resolve this latter problem. The issue of reliability of diagnosis 
can be significant,14 but is largely resolved at the point of death in a 
global category such as “nervous disease deaths”.1,5-8 It is acknowl-
edged that 100% accuracy can never be established, but as the WHO 
data are collected in a consistent and uniform system in these broad 
categories this is probably the most reliable and valid international 
data as yet available.
2.1 | Statistics
Confidence intervals (to ±95% significance) are used to compare 
changes between the control mortalities and TND over the period and 
between the USA and the other countries. Spearman’s rank order cor-
relation examines any link between increases in neurological mortality 
any decreases in either Cancer or CDD deaths. Odds ratio calculates 
proportional differences between ratios of change, from which a ratio 
of ratios is calculated. An example best explains this. Rises in neuro-
logical deaths5,7,8 had been attributed to rises in population15-17. Odds 
ratio tests this using the ratio of change in the USA elderly population, 
1989 and 2014, giving a ratio of 1.49 and divides it into the ratio of 
change of neurological deaths, 5.13 and the ensuing ratio of ratios is 
the odds ratio of 3.44.
3  | RESULTS
3.1 | Male (55- 74) TND
Table 1 lists adult (55- 74) Male Total Neurological Deaths (TND) 
ranked by the highest frequency ranging from Finland at 1070 per 
million (pm), USA 690 pm and Belgium 645 pm down to Japan 270 pm, 
Greece 307 pm and Austria 363 pm.
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Neurological deaths rose by >10% in eleven countries—Portugal 
72% Greece 65%, Denmark and Finland 63%, the USA 43%, Spain 
39%, Japan 32%, Germany 28%, Sweden 18%, Norway 15% and 
Australia, 13%. There were falls >5 in Belgium, Canada, France and 
New Zealand. In the earlier 1989- 91 period, the USA was the 10th 
highest of the twenty- one countries but is now second highest.
3.2 | Female (55- 74) TND
The highest rates were Finland 924 pm, USA 618 pm and the UK 
564 pm, the lowest being Japan 176 pm, Greece 252 pm and Austria 
334 pm.
Ten countries female rates rose by more than >10% in Portugal 
96%, the USA 68%, Greece and Finland 53%, Netherlands 38%, 
Denmark 35%, Spain 12%, Australia 17%, Germany 16% and Ireland 
14%. There were falls in Belgium of 16%, France 6% and Canada 4%. 
At the base- line years, USA female rates were 11th highest but are 
now second.
Male and female current rates were significantly correlated 
(Rho=+0.7714, P<.001).
Over the period, there were only few changes between the gen-
der, male and female 1989- 91 rates correlated (Rho=+0.8263) and in 
2012- 14 (Rho=+0.8429, P<.001).
3.3 | Over- 75s TND as context 1989- 2014
Table 2 lists over- 75s rates of both sexes and population in-
creases. The highest was Finland at 20 562 pm followed by the 
USA at 17 207, the Netherlands at 13 145 pm the lowest being 
Greece 1382, Canada 1746 pm and Japan 2479 pm. Previously 
the USA had been 9th highest of 21 countries. There was a posi-
tive  correlation between increases in the 55- 74 and over- 75s 
(Rho=+0.8760, P<.001) indicating consistency across the countries 
under review.
The USA had substantially the biggest rise, up fourfold, whilst the 
elderly American population increased by just 49%, yielding an odds 
TABLE  1 Changes in Total Neurological Deaths (TND) rates per million (pm) by gender (55- 74) & ratio of change 1989- 91 v 2012- 14 ranked 
by highest male rates
Country and years
TND 
Male 
1989
TND 
Male 
2014 Ratio of change
TND 
Female 
1989
TND 
Female 
2014 Ratio of change
1. Finland 2012- 14 657 1070 1.63 604 924 1.53
2. USA 2012- 14 481 690 1.43 367 618 1.68
3. Belgium 2011- 13 658 645 0.98 562 472 0.84
4. UK 2011- 13 579 629 1.09 525 564 1.07
5. Sweden 2012- 14 377 604 1.18 510 540 1.03
6. Norway 2012- 14 525 602 1.15 539 554 1.03
7. Denmark 2012- 14 346 565 1.63 377 509 1.35
8. Netherlands 
2012- 14
520 564 1.08 354 487 1.38
9. Ireland 2011- 13 523 538 1.03 428 488 1.14
10. Spain 2012- 14 378 527 1.39 356 400 1.12
11. France 2011- 13 525 517 0.98 401 375 0.94
12. Germany 2012- 14 403 516 1.28 339 392 1.16
13. Switzerland 
2011- 13
530 510 0.96 466 471 1.01
14. Australia 2012- 14 451 510 1.13 365 427 1.17
15. Canada 2010- 12 523 493 0.94 430 414 0.96
16. Italy 2010- 12 456 479 1.05 367 374 1.02
17. Portugal 2012- 14 271 467 1.72 204 399 1.96
18. N. Zealand 
2010- 12
446 462 0.99 402 414 1.03
19. Austria 2012- 14 349 363 1.04 314 334 1.06
20. Greece 2011- 13 186 307 1.65 165 252 1.53
21. Japan 2012- 14 206 270 1.32 173 176 1.02
Rest (- US) Average 445 532 1.20 394 448 1.14
Rest average:USA 
ratio
1:1.08 1:1.30 1:1.19 1:0.93 1:1.38 1:1.47
The values for USA are highlighted in bold.
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ratio of 1:3.44. The average population rise in the other countries 
was 56% with TND rising on average 187%, yielding an odds ratio 
of 1:1.84. Except Belgium and Greece, every country’s population 
to TND odds ratio rose substantially (1:1.25) ten doubling over the 
period.
3.4 | USA v other countries
Table 3 presents USA male rates compared with each of the other 
twenty countries using confidence intervals (±95%) shaded areas 
showing significant differences. The USA had significantly greater 
TABLE  2 Both sexes over- 75’s Total Neurological Death (TND) rates per million 1989- 2014 ratio of change and total population to TND 
odds ratios (Doubled in BOLD). Ranked by highest TND
Country Population 1989 Ratio of change TND Ratio of change Odds ratio
1. Finland 1989 
2014
0.281 
0.459
1.63 7204 
20 562
2.85 1:1.75
2. USA 1989 
2014
13.103 
19.477
1.49 3355 
17 207
5.13 1:3.44
3. Netherlands 1989 
2014
0.814 
1.221
1.50 3420 
13 145
3.84 1:2.56
4. Sweden 1995 
2014
0.683 
0.816
1.20 3322 
12 956
3.90 1:3.25
5. UK 1989 
2013
3.987 
5.036
1.26 4767 
12 780
2.68 1:2.13
6. Switzerland 1989 
2013
0.471 
0.647
1.37 7344 
12 521
1.71 1:1.25
7. Norway 1989 
2014
0.299 
0.354
1.18 3297 
11 261
3.43 1:2.90
8. Spain 1989 
2014
2.142 
4.271
1.99 3290 
11 221
3.41 1:1.71
9. France 1989 
2013
3.931 
5.785
1.47 4227 
11 066
2.62 1:1.78
10. Australia 1989 
2014
0.744 
1.496
1.98 4488 
11 064
2.47 1:1.25
11. Denmark 1994 
2014
0.362 
0.411
1.14 2279 
10 685
4.69 1:4.11
12. Belgium 1989 
2014
0.659 
0.969
1.47 8101 
10 337
1.28 1:0.87
13. Ireland 1989 
2013
0.159 
0.235
1.48 3329 
9835
2.95 1:1.99
14. N. Zealand 1989 
2012
0.152 
0.263
1.73 3265 
9222
2.82 1:1.63
15. Italy 1989 
2012
3.678 
6.139
1.67 2493 
7105
2.81 1:1.68
16. Germany 1990 
2014
5.549 
8.178
1.47 1977 
5919
2.99 1:2.03
17. Austria 1989 
2014
0.527 
0.693
1.31 1640 
5540
3.38 1:2.58
18. Portugal 1989 
2014
0.527 
1.006
1.91 899 
5537
6.16 1:3.23
19. Japan 1989 
2014
5.974 
15.521
2.60 759 
2479
3.27 1:1.26
20. Canada 1989 
2012
1.296 
2.297
1.77 484 
1746
3.61 1:2.04
21. Greece 1989 
2013
0.608 
1.112
1.83 1080 
1382
1.28 1:0.70
Rest average (- US) 1.56 3383 
9718
2.87 1:1.84
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rises than twelve other countries, and no country had bigger increases 
than the USA.
USA female rates rose significantly more than seventeen other 
countries, whilst no other country had bigger increases than the USA.
3.5 | Control mortalities
3.5.1 | Males: Cancer
Table 4 present changes in Cancer and CDD over the period, ranked 
by the highest CDD.
In respect to cancer deaths, the current Western average (minus 
the USA) was 5511 pm, representing a fall over the period of 26%. The 
highest rate was France at 6322 pm, the lowest Switzerland 3956 pm, 
with the USA being fifth lowest at 4908 pm, representing a fall of 41% 
over the period.
There was a significant negative correlation between decreases in 
cancer mortality with increases in neurological death (Rho=−0.4521, 
P<.025).
3.5.2 | Male CDD
The initial Western average rate was 9118 pm falling to 3321 pm, an 
equivalent fall of 64%. The highest CDD was Finland 5056 pm, the 
lowest France 2354 pm, the USA was third highest at 4509 pm but 
equivalent to a fall of 58%.
There was a slight none significant negative correlation between 
decreases in CDD and rises in neurological deaths (Rho=−0.2050 
n.sig).
3.5.3 | Females: Cancer
Table 4 shows female cancer rates, the Western average being 3514 
pm, representing a fall of 21%. The highest was Denmark 4849 pm the 
lowest Japan at 2706 pm. The USA at 3048 pm was the fifth lowest, 
equivalent to a fall of 46% over the period.
There was no significant correlation between decreases in fe-
male cancer and increases in neurological deaths (Rho=−0.1312 
n.sig).
3.5.4 | Female CDD
The Western average was 1432 pm, representing a fall of 67% 
over the period, the highest was the USA 3879 pm, although equiv-
alent to a 46% reduction over the period, the lowest was France 
852 pm.
There was no significant correlation between decreases in CDD 
and rises in neurological deaths (Rho=−0.2618 n.sig).
Country
Male Female
OR Lower Upper OR Lower Upper
Australia 1:1.27 1:1.07 1:1.51 1:1.44 1:1.19 1:1.74
Austria 1:1.38 1:1.14 1:1.66 1:1.58 1:1.29 1:1.94
Belgium 1:1.46 1:1.25 1:1.72 1:2.01 1:1.68 1:2.4
Canada 1:1.52 1:1.28 1:1.8 1:1.75 1:1.45 1:2.11
Denmark 1:0.88 1:0.74 1:1.05 1:1.25 1:1.04 1:1.5
Finland 1:0.88 1:0.76 1:1.03 1:1.10 1:0.93 1:1.3
France 1:1.46 1:1.23 1:1.72 1:1.80 1:1.49 1:2.18
Germany 1:1.12 1:0.94 1:1.33 1:1.46 1:1.20 1:1.77
Greece 1:0.87 1:0.70 1:1.08 1:1.10 1:0.87 1:1.39
Ireland 1:1.39 1:1.18 1:1.65 1:1.48 1:1.23 1:1.77
Italy 1:1.37 1:1.15 1:1.62 1:1.65 1:1.36 1:2.01
Japan 1:1.09 1:0.88 1:1.36 1:1.66 1:1.29 1:2.12
Netherlands 1:1.32 1:1.12 1:1.56 1:1.22 1:1.01 1:1.48
New Zealand 1:1.38 1:1.16 1:1.65 1:1.64 1:1.35 1:1.97
Norway 1:1.25 1:1.06 1:1.48 1:1.64 1:1.37 1:1.95
Portugal 1:0.83 1:0.69 1:1.01 1:0.86 1:0.70 1:1.06
Spain 1:1.03 1:0.86 1:1.23 1:1.50 1:1.24 1:1.82
Sweden 1:0.90 1:0.75 1:1.07 1:1.59 1:1.33 1:1.9
Switzerland 1:1.49 1:1.26 1:1.76 1:1.67 1:1.39 1:2
UK 1:1.32 1:1.12 1:1.55 1:1.57 1:1.32 1:1.87
USA 1:10 1:0.85 1:1.18 1:10 1:0.83 1:1.2
Grey areas statistically significant (±95%).
TABLE  3 Confidence intervals 
comparing other countries v USA 
neurological death rates 1989- 2014.
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3.5.5 | Comparing control to neurological deaths
Table 5 provides the confidence interval results comparing male 
cancer to neurological and CDD to neurological deaths over the 
period.
Every country’s neurological deaths worsened significantly in com-
parison with the control deaths.
This pattern was found for Female cancer and CDD neurological 
seventeen and nineteen countries, respectively.
3.5.6 | Rates are statistics—numbers people
Mortality rates are “statistics,” whereas actual numbers of people can 
give a better feel to the practice reality of these increases.
In 1979, there were 28 261 American TND deaths of which 
11 033 were in the 55- 74 age band. By 1989, these had risen to 
65 656 and 16 677, respectively. By 2014, there were 405 187 TND 
deaths of which 44 825 people aged 55- 74 had died of a neurolog-
ical condition. Thus, over 25 years, albeit within a growing elderly 
population, there were an “extra” 339 31 people dying from a neu-
rological condition, of which an “extra” 28 148 were under 74 years 
old. Such numbers of people dying in such a relatively short time 
is an indication of the extent of the likely pressure on families and 
services.
4  | CONCLUSIONS
4.1 | Limitations to the study
Death rates depend upon the reliability of diagnosis, which some be-
lieve have resulted in higher specific diagnosis of ALS.14 However, as 
the measures are in the broad category of neurological diseases, this 
is less of a problem [1.5- 8]. The claims that increases in neurological 
morbidity are due to the Gompertzian effect15-17 is largely questiona-
ble, as the 55- 74 age band is below current Western life expectancy.23 
Moreover, the fourfold rise in the American over- 75s TND rates, 
emerged from just a 49% increase of the elderly population counters 
a primarily Gompertzian explanation.
Finally, aggregated international studies cannot account for any 
particular country’s substantial changes, which will require country- 
specific research possibly requiring a geo- epidemiology approach 
which involves detailed mapping of cases right down to houses in 
street locations.24
4.2 | Main findings
We can reject all four null hypotheses as neurological deaths rose sig-
nificantly more than the control deaths in every country and for both 
sexes. Furthermore, whilst no other country had greater rises in their 
neurological deaths than the USA, American male and female neu-
rological deaths rose significantly more than twelve and seventeen 
countries, respectively, occurring only just 25 years. Furthermore, 
there was no positive statistical link between increases in neurological C
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deaths and decreases in the control mortalities, which would have 
been expected if the Gompertzian was a strong factor. Moreover, com-
pared with the earlier analyses between 1989 and 2010 where there 
were notable rises in males in six countries and in four countries for 
females, by 2014 there had been rises of equivalent to >10% in twelve 
countries for men and in eleven countries for females. A Gompertzian 
perspective also ignores rises in early onset dementia (EOD) reported 
in many countries.4-13,19,20,22,25 For example, one found 29% of their 
cohort were aged under 65 years, which 30 years before would have 
been considered extraordinary.4-13,19,20,22,25 Another indication of the 
extent of increased EOD is seen in examining Medline studies related 
to EOD. The first paper was published June 1967 by June 1987 there 
were 100 papers, whereas from January to December 2016, there 
were 299 directly or indirectly related to EOD, clearly whatever the 
multiple causal explanations, something has changed.
Moreover, the over- 75’s TND results showed that the increases 
were essentially far in excess of rises in the over- 75’s population. 
Whilst there may be some Gompertzian influences related to demog-
raphy it does not appear to be the predominant factor, especially in the 
USA and nine other countries whose elderly population to TND rates 
produced odds ratios that had more than doubled.
The study adds confirmation that the changes noted at the end of 
the last century, are continuing, and despite the limitations, provides 
valid data for future research, whilst raising questions as to what might 
account for these global changes.
Although this study does not attempt to explain the reasons behind 
these increases, it is clear that the neurological morbidity is starting 
earlier and the reported rises are not primarily an artefact. There are 
confirmed rises of ALS from a number of Western clinical studies1-13,25 
as well as small increases in Asian and Latin American countries.18,19
This is not to discount studies that identified genetic and familial 
patterns20-22 but others recognize lifestyle and possible interactive 
environmental contributions.2,4,6-8,25 Including such factors as occupa-
tion, heavy metals, petro- chemicals, organophosphate/pesticides26-30 
and possible influence of electromagnetic field (EMF)18,25,31 and mili-
tary service.32 Although not all studies related to ALS have consistently 
reported environmental factors,33 the majority have highlighted envi-
ronmental factors rather than longevity4-8,18,25-30 as well as epigenetic 
changes,33-35 whist recently, research had linked rises in dementias to 
proximity to major roads.30
This project is not equipped to explain the reasons behind these 
changes, but in view of the relatively short period, it is indicative that 
TABLE  5 Confidence intervals male and female 55- 74 cancer v Total Neurological Deaths and CDD v Total Neurological Deaths 1989- 2013
Confidence intervals—Cancer: ND/CDD: TND MALES Confidence intervals—Cancer: ND/CDD:TND FEMALES
 Cancer: ND CDD: ND Cancer: ND CDD: ND
 OR Lower Upper OR Lower Upper OR Lower Upper OR Lower Upper
Australia 1:1.76 1:1.54 1:2.01 1:4.31 1:3.76 1:4.93 1:1.63 1:1.41 1:1.89 1:5.21 1:4.46 1:6.09
Austria 1:1.35 1:1.16 1:1.57 1:2.59 1:2.23 1:3.02 1:1.24 1:1.05 1:1.45 1:2.97 1:2.52 1:3.5
Belgium 1:1.36 1:1.22 1:1.53 1:2.24 1:2.20 1:2.52 1:0.94 1:0.82 1:1.07 1:1.97 1:1.72 1:2.26
Canada 1:1.49 1:1.31 1:1.69 1:2.57 1:2.26 1:2.93 1:1.24 1:1.07 1:1.42 1:2.67 1:2.30 1:3.10
Denmark 1.2.32 1:2.03 1:2.67 1:5.19 1:4.51 1:5.97 1:1.87 1:1.3 1:2.15 1:4.46 1:3.85 1:5.17
Finland 1:2.36 1:2.12 1:2.61 1:4.28 1:3.86 1:4.74 1:1.85 1:1.65 1:2.07 1:7.11 1:6.31 1:8.01
France 1:1.25 1:1.10 1:1.42 1:2.35 1:2.06 1:2.68 1:1.05 1:0.91 1:1.22 1:2.23 1:1.90 1:2.62
Germany 1:1.54 1:1.35 1:1.77 1:2.89 1:2.52 1:3.31 1:1.32 1:1.13 1:1.53 1:2.81 1:2.41 1:3.28
Greece 1:1.66 1:1.38 1:1:20 1:2.68 1:2.22 1:3.22 1:1.31 1:1.31 1:1.97 1:2.56 1:2.09 1:3.13
Ireland 1:1.52 1:1.34 1:1.73 1:3.79 1:3.34 1:4.3 1:1.34 1:1.54 1:1.76 1:4.12 1:4.74 1:5.46
Italy 1:1.53 1:1.34 1:1.75 1:2.26 1:1.98 1:2.59 1:1.01 1:1.18 1:1.37 1:1.91 1:2.24 1:2.62
Japan 1:1.53 1:1.27 1:1.84 1:2.14 1:1.78 1:2.58 1:1.14 1:0.91 1:1.41 1:2.42 1:1.94 1:3.03
Netherlands 1:1.56 1:1.38 1:1.77 1:4.06 1:3.57 1:4.61 1:1.45 1:1.25 1:1.67 1:3.90 1:3.35 1:4.53
N. Zealand 1:1.59 1:1.39 1:1.81 1:3.35 1:2.93 1:3.84 1:1.49 1:1.29 1:1.72 1:3.68 1:3.17 1:4.26
Norway 1:1.70 1:1.50 1:1.92 1:4.92 1:4.34 1:5.57 1:1.30 1:1.15 1:1.48 1:4.31 1:3.77 1:4.94
Portugal 1:1.76 1:1.51 1:2.06 1:5.01 1:4.29 1:5.85 1:2.33 1:1.95 1:2.77 1:7.09 1:5.93 1:8.48
Spain 1:1.43 1:1.25 1:1.64 1:3.07 1:2.67 1:3.53 1:3.31 1:1.13 1:1.53 1:2.64 1:2.26 1:3.09
Sweden 1:2.22 1:1.94 1:2.54 1:4.76 1:4.17 1:5.45 1:1.36 1:1.20 1:1.55 1:3.28 1:2.86 1:3.77
Switzerland 1:1.59 1:1.40 1:1.81 1:2.17 1:1.91 1:2.47 1:1.18 1:1.03 1:1.36 1:2.28 1:1.97 1:2.64
UK 1:1.64 1:1.45 1:1.84 1:4.14 1:3.26 1:4.14 1:1.50 1:1.32 1:1.69 1:4.08 1:3.58 1:4.65
USA 1:2.43 1:2.15 1:2.74 1:3.39 1:3.30 1:3.83 1:3.12 1:2.73 1:3.58 1:3.70 1:3.24 1:4.23
Shading indicates significant differences at ±95%.
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multi- interactive environmental factors are probably having a greater 
influence.
Focusing only on the USA in 1989- 91, male neurological rates 
were ninth highest and are now second highest and American females 
moved from being twelfth to fourth highest. There is an urgent need 
to explain these remarkable changes.
At a practice level, both families and the medical specialities deal-
ing with the concomitant problems of neurological disease are in dan-
ger of being overwhelmed. In particular, is issue of relatively younger 
neurological patients burden upon their families, complicated by the 
psychiatric and psychosocial problems associated with neurological 
disease. Moreover, until the extent of these changes is recognized the 
present configuration of services will be overwhelmed. Consequently, 
there is an urgent need for cross- disciplinary research to understand 
the underlying interactive processes that contribute to rises in neu-
rological morbidity and mortality and for the necessary community- 
based support that will be needed until or if effective preventative 
and/or treatments can be introduced.
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